Alumis Inc., a late-stage biopharma company specializing in next-generation targeted therapies for immune-mediated diseases, has successfully completed its merger with ACELYRIN, Inc. This strategic move establishes a leading clinical-stage biopharma company with a robust portfolio and a strong financial position. As part of the merger, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share they own. With this merger, Alumis aims to advance its pipeline and extend its cash runway into 2027, ensuring continued development of transformative therapies for patients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。